NCT03400800已完成3 期
A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,617
- 试验地点
- 70
- 主要终点
- Percentage Change in LDL-C From Baseline to Day 510
研究概览
简要总结
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be an international multicenter study (non-United States).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants may be included if they meet all of the following inclusion criteria prior to randomization:
- •Male or female participants ≥18 years of age.
- •History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or peripheral arterial disease [PAD]).
- •Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).
- •Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.
- •Calculated glomerular filtration rate >30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology
- •Participants on statins should be receiving a maximally tolerated dose.
- •Participants not receiving statins must have documented evidence of intolerance to all doses of at least 2 different statins.
- •Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation.
- •Subjects were willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures
排除标准
- •Participants will be excluded from the study if any of the following exclusion criteria apply prior to randomization:
- •New York Heart Association (NYHA) class IV heart failure.
- •Uncontrolled cardiac arrhythmia.
- •Uncontrolled severe hypertension.
- •Active liver disease.
- •Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least 2 methods of highly effective contraception (failure rate less than 1% per year) (for example, combined oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:
- •Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age.
- •Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
- •Women who are surgically sterilized at least 3 months prior to enrollment.
- •Males who are unwilling to use an acceptable method of birth control during the entire study period (such as condom with spermicide).
- •Treatment with other investigational products or devices within 30 days or 5 half-lives of the screening visit, whichever is longer.
- •Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK
- •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
研究组 & 干预措施
Inclisiran
Experimental
Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
干预措施: Inclisiran Sodium (Drug)
Saline Solution
Placebo Comparator
Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage Change in LDL-C From Baseline to Day 510
时间窗: Baseline, Day 510
Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540
时间窗: Baseline, Day 90 to Day 540
次要结局
- Absolute Change In LDL-C From Baseline To Day 510(Baseline, Day 510)
- Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540(Baseline, Day 90 to Day 540)
- Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510(Baseline, Day 510)
- Percentage Change in Total Cholesterol From Baseline to Day 510(Baseline, Day 510)
- Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510(Baseline, Day 510)
- Percentage Change in Non-HDL-C From Baseline to Day 510(Baseline, Day 510)
研究者
研究点 (70)
Loading locations...
相似试验
已完成
3 期
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein CholesterolASCVDElevated CholesterolNCT03399370The Medicines Company1,561
已完成
3 期
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological CancersChemotherapy-induced ThrombocytopeniaNCT03471078Sobi, Inc.122
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyBreast CancerNCT04873362Hoffmann-La Roche1,188
已完成
3 期
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaMelanomaNCT02908672Hoffmann-La Roche514
尚未招募
3 期
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyPlaque PsoriasisNCT06643260Can-Fite BioPharma705